IBD: Taking aspirin daily does not affect the clinical efficacy of patients with inflammatory bowel disease

BACKGROUND: Although several studies have confirmed a correlation between the use of nonsteroidal anti-inflammatory drugs and the onset of inflammatory bowel disease (IBD), little is known about the impact of daily aspirin on clinical outcomes in IBD patients.
, this study is intended to assess this.
method researchers conducted a retrospective analysis of IBD patients between May 2008 and June 2015.
IBD patients who took aspirin daily were matched by age, sex, disease, disease location, and whether or not to take aspirin.
observations were IBD-related hospitalizations, IBD-related surgery, and the need for corticosteroid treatment during follow-up.
results The study included a total of 764 IBD patients, 174 of whom were taking aspirin.
There were no statistical differences in age, sex, diagnosis (Crohn's disease and ulcerative colitis), duration of the disease, Charsen's combined index, smoking status, drug use or baseline C-reactive proteins between the two groups.
After controlling the covariance and follow-up time of the entire population, the use of aspirin was independent of the risk of hospitalization for IBD-related complications (OR, 1.46; P s 0.10), corticosteroid use (OR, 0.99; P s 0.70) or IBD-related surgery (OR, 0.99; P s 0.96).
conclusions, the researchers say aspirin use does not affect the main clinical outcomes in IBD patients.
although the effects of aspirin on mucous membrane inflammation were not directly assessed in this study, these findings support the safety of daily aspirin use in this population.